药物基因组学指导全膝关节置换术后个体化疼痛管理方案
该试点研究对31例初次全膝关节置换患者进行药物基因组学检测,评估影响非甾体抗炎药和阿片类药物代谢的基因变异频率,并将患者随机分为标准镇痛方案组和基于基因结果定制方案组。结果显示42%患者存在影响多模式镇痛方案中至少一种药物的基因变异,定制组前10天平均疼痛评分和吗啡当量消耗均低于对照组。
要点
- 42%的全膝关节置换患者存在影响围手术期镇痛药物代谢的基因变异。
- 基于药物基因组学定制镇痛方案可能降低术后疼痛评分。
- 需进一步研究确认基因指导用药对临床结局的改善作用。
核心结论
- 42%的患者存在涉及围手术期镇痛方案中至少一种药物的基因变异。
- 基于药物基因组学结果定制镇痛方案可能改善疼痛控制,但需进一步研究确认。
研究设计与样本
- 试点研究,收集31例初次全膝关节置换患者的口腔拭子样本进行药物基因组学检测。
- 检测基因包括OPRM1、CYP1A2、CYP2B6、CYP2C19、CYP3A4、CYP2C9和CYP2D6。
- 患者随机分为对照组(标准术后镇痛方案)和研究组(基于药物基因组学结果的定制方案)。
- 患者记录术后前10天的疼痛评分、用药和副作用。
主要发现
- 31例患者中13例(42%)存在涉及一种或多种镇痛药物的基因变异。
- 8例患者(26%)存在影响超过一种药物的基因变异。
- 在记录疼痛和用药日志的25例患者中,对照组前10天平均疼痛水平和吗啡当量消耗高于定制组(疼痛p=0.019,吗啡当量p=0.655)。
关键数值与推荐
- 基因变异涉及药物包括塞来昔布、氢可酮和曲马多。
- 疼痛评分比较p=0.019,吗啡当量消耗比较p=0.655。
临床怎么用
- 可考虑对全膝关节置换患者进行药物基因组学检测以指导镇痛药物选择。
- 根据基因变异结果调整多模式镇痛方案可能优化疼痛控制。
局限性
- 试点研究样本量小(31例),需更大规模研究验证。
- 仅25例患者完成疼痛和用药日志记录。
- 研究未报告基因指导用药对副作用的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The purpose of this study was to use pharmacogenetics to determine the frequency of genetic variants in our total knee arthroplasty (TKA) patients that could affect postoperative pain medications. Pharmacogenetic testing evaluates patient DNA to determine if a drug is expected to have a normal clinical effect, heightened effect, or no effect at all on the patient. It also predicts whether patients are likely to experience side effects from medicine. We further sought to determine if changing the multimodal programme based on these results would improve pain control or reduce side effects. METHODS: In this pilot study, buccal samples were collected from 31 primary TKA patients. Pharmacogenetics testing examined genetic variants in genes OPRM1, CYP1A2, CYP2B6, CYP2C19, CYP3A4, CYP2C9, and CYP2D6. These genes affect the pharmacodynamics and pharmacokinetics of non-steroidal anti-inflammatory drugs and opioids. We examined the frequency of genetic variants to any of the medications we prescribed including celecoxib, hydrocodone, and tramadol. Patients were randomized to one of two groups: the control group received the standard postoperative pain regimen, and the study group received a customized regimen based on the pharmacogenetic results. For the first ten postoperative days, patients recorded pain scores, medication, and side effects. RESULTS: Genetic variants involving one or more medications in the multimodal pain protocol occurred in 13 of the 31 patients (42%). In total, eight patients (26%) had variants affecting more than one of the medications. For the 25 patients who recorded pain and medication logs, the mean pain levels and morphine equivalents (MEQs) consumed in the first ten days were higher in the control group than in the custom-guided group (p = 0.019 for pain and p = 0.655 for MEQ). CONCLUSION: Overall, 42% of patients had a variant involving one of the pain medications prescribed in our perioperative pain program for TKA. Ongoing research will help determine if using these data to modify a patient's medication will improve outcomes. Cite this article: Bone Joint J 2020;102-B(6 Supple A):73-78.
引用
- Hamilton WG, Gargiulo JM, Parks NL, et al. Using pharmacogenetics to structure individual pain management protocols in total knee arthroplasty. Bone Joint J. 2020. PMID: 32475277. doi:10.1302/0301-620X.102B6.BJJ-2019-1539.R1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。